Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant

Breast Cancer Research and Treatment

Volumn 117, Issue 1, 2009, Pages 77-81

  Morales, Leilani ^a   Neven, Patrick ^a   Timmerman, Dirk ^a   Wildiers, Hans ^a   Konstantinovic, Maja L ^a   Christiaens, Marie Rose ^a   Tan, Peter N ^b   Paridaens, Robert ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Breast cancer; Endometrium; Fulvestrant; Hormonal therapy; Ultrasonography; Uterus

Indexed keywords

AROMATASE INHIBITOR; FULVESTRANT; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM CANCER; FEMALE; HUMAN; METASTASIS; POSTMENOPAUSE; PRIORITY JOURNAL; TRANSVAGINAL ECHOGRAPHY; UTERUS MALFORMATION; VAGINA BLEEDING;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ENDOMETRIUM; ENDOSONOGRAPHY; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE;

EID: 69049097170     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0248-2     Document Type: Article

References (31)

1. P Neven X De Muylder Y Van Belle et al. 1989 Tamoxifen and the uterus and endometrium Lancet 1 375 10.1016/S0140-6736(89)91741-8
2. T Fornander LE Rutquivist N Wilking 1991 Effects of tamoxifen on the female genital tract Ann N Y Acad Sci 622 469 476 10.1111/j.1749-6632.1991. tb37890.x
3. RP Kedar TH Bourne TJ Powles et al. 1994 Effects of tamoxifen on the uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial Lancet 343 1318 1321 10.1016/S0140-6736(94)92466-X
4. B Fisher JP Constantino DL Wickerham et al. 1998 Tamoxifen for prevention of breast cancer. Report of the national surgical adjuvant breast and bowel project P-1 study J Natl Cancer Inst 90 1371 1388 10.1093/jnci/90.18.1371
5. L Morales P Neven R Paridaens 2005 Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting Curr Opin Oncol 17 559 565 10.1097/01.cco.0000180434.31991.bf
6. R Poole R Paridaens 2007 The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review Curr Opin Oncol 19 564 572
7. B Thuerlimann D Koeberle HJ Senn 2007 Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: past, present and future recommendations Eur J Cancer 43 46 52 10.1016/j.ejca.2006. 09.003
8. L Morales D Timmerman P Neven et al. 2005 Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients Ann Oncol 16 70 74 10.1093/annonc/mdi021
9. O Garrone S Mezi M Occelli 2003 Reversal of tamoxifen induced endometrial modifications by switching to letrozole in early breast cancer patients: a prospective TVUS study Ann Oncol 14 s22
10. S Duffy TL Jackson M Lansdown et al. 2006 The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment Hum Reprod 21 545 553 10.1093/humrep/dei322
11. B Gerber A Krause T Reimer et al. 2006 Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology Clin Cancer Res 12 1245 1250 10.1158/1078-0432.CCR-05-0225
12. G Garuti F Cellani G Centinaio et al. 2006 Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors Gynecol Oncol 103 599 603 10.1016/j.ygyno.2006.04.004
13. O Markovitch R Tepper A Fishman et al. 2007 Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients Breast Cancer Res Treat 101 185 190 10.1007/s10549-006-9285-x
14. G Bertelli E Hall E Ireland et al. 2007 Endometrial status in the Intergroup Exemestane Study (IES) up to 2 years post-treatment Breast Cancer Res Treat 106 s111
15. DG Kieback N Harbeck W Bauer et al. 2008 Endometrial safety of cross-over treatment with tamoxifen followed by exemestane Eur J Cancer 6 s198
16. MC Boruban K Altundag GS Kilic J Blankstein 2008 From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures Eur J Cancer Prev 17 133 138
17. JFR Robertson 2001 Faslodex (ICI 182, 780), a novel estrogen receptor downregulator-future possibilities in breast cancer J Steroid Biochem Mol Biol 79 209 212 10.1016/S0960-0760(01)00138-8
18. A Howell J Pippen RM Elledge et al. 2005 Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma Cancer 104 236 239 10.1002/cncr.21163
19. L Perey R Paridaens H Hawle et al. 2007 Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00) Ann Oncol 18 64 69 10.1093/annonc/mdl341
20. P Neven R Paridaens G Pelgrims et al. 2008 Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study Breast Cancer Res Treat 109 59 65 10.1007/s10549-007-9628-2
21. JF Robertson SE Come SE Jones et al. 2005 Endocrine treatment options for advanced breast cancer-the role of fulvestrant Eur J Cancer 41 346 356 10.1016/j.ejca.2004.07.035
22. S Chia W Gradishar L Mauriac et al. 2008 Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior non-steroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT J Clin Oncol 26 1664 1670 10.1200/JCO.2007.13.5822
23. A Gaducci S Cosio AR Genazzani 2004 Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body Curr Opin Investig Drugs 5 1031 1044
24. S Addo RA Yates A Laight 2002 A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers Br J Cancer 87 1354 1359 10.1038/sj.bjc. 6600644
25. J Donnez BH Vivancos M Kudela et al. 2003 A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy Fertil Steril 79 1380 1389 10.1016/S0015-0282(03)00261-9
26. M Lux E Wenkel K Beckmann et al. 2006 Fulvestrant: a further treatment option for patients with metastatic uterine cancer? Onkologie 29 577 580 10.1159/000096541
27. MA Hoffman A Khan 2006 Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy Gynecol Oncol 100 439 441 10.1016/j.ygyno.2005.09.011
28. World Medical Association (2008) Review of the declaration of Helsinki. http://www.wma.net
29. P Neven I Vergote 1998 Should tamoxifen users be screened for endometrial lesions? Lancet 351 155 157 10.1016/S0140-6736(05)78216-7
30. M Berlière C Galant A Charles et al. 2002 Endometrial evaluation is a very important tool in the management of breast cancer patients Eur J Cancer 38 suppl. 6 67 68 10.1016/S0959-8049(02)00292-7
31. L Morales R Paridaens D Timmerman P Neven 2006 Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathology Clin Cancer Res 12 5603 10.1158/1078-0432.CCR-06-0897